1. Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study;Accurso;Hematol. Rep.,2019
2. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β;Agarwal;Stem Cell investig.,2016
3. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis (N= 2233);Al-Ali;Blood,2017
4. KRT-232, A first-in-class, murine double minute 2 inhibitor, for myelofibrosis relapsed or refractory to janus-associated kinase inhibitor treatment;Al-Ali;Hemasphere.,2020
5. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts;Al-Ali;Br. J. Haematol.,2020